3 completed, 1 active not recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
Follow Adult Erythroleukemia: new trials by email Literature Review of Adult Erythroleukemia trials Research Report on Adult Erythroleukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2013-05-01 | 2016-09-01 |
| Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Tipifarnib, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-05-01 | 2015-04-08 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 68 | 2010-07-15 | 2022-08-04 |
| Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Azacitidine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 133 | 2008-12-01 | 2026-10-22 |
Leukemia, Erythroblastic, Acute (4) · Leukemia, Megakaryoblastic, Acute (4) · Leukemia, Monocytic, Acute (4) · Leukemia, Myeloid, Acute (4) · Leukemia, Myelomonocytic, Acute (4) · Anemia, Refractory, with Excess of Blasts (1) · Myelodysplastic Syndromes (1)
Bone Marrow Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myeloid (4) · Myeloproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Anemia (1) · Anemia, Refractory (1)
Azacitidine (2) · Antilymphocyte Serum (1) · Busulfan (1) · Cytarabine (1) · Gemtuzumab (1) · MK-8776 (1) · Methotrexate (1) · Stem Cell Transplantation (1) · Tacrolimus (1) · fludarabine phosphate (1) · merphos (1) · tipifarnib (1)
National Cancer Institute (NCI) (4)
United States (4)
B. Smith (1) · Jeffrey Lancet (1) · Ravi Vij (1) · Sucha Nand (1)
U01CA070095 (2), N01CM00071 (1), N01CM00100 (1), P30CA006973 (1), P30CA076292 (1), U10CA031946 (1), U10CA032102 (1), U10CA180821 (1)